Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler Sells 4,536 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the transaction, the chief marketing officer now owns 95,671 shares of the company’s stock, valued at approximately $1,268,597.46. The trade was a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Evolus Stock Performance

Shares of EOLS opened at $13.25 on Friday. The firm has a market capitalization of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a 50-day moving average price of $13.36 and a 200 day moving average price of $13.91. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82.

Analyst Upgrades and Downgrades

EOLS has been the subject of several analyst reports. Barclays boosted their price target on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. KBC Group NV acquired a new position in shares of Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after acquiring an additional 4,709 shares during the period. Point72 Asset Management L.P. bought a new stake in Evolus in the third quarter worth about $132,000. KLP Kapitalforvaltning AS acquired a new stake in Evolus in the 4th quarter valued at about $106,000. Finally, Rafferty Asset Management LLC bought a new position in shares of Evolus during the 4th quarter valued at about $115,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.